Welcome to our dedicated page for Coeptis Therapeutics news (Ticker: COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics stock.
Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP) combines biopharmaceutical innovation with advanced technology solutions, focusing on cell therapy platforms and AI-driven operational strategies. This page serves as the definitive source for tracking the company’s latest developments across both sectors.
Investors and industry observers will find timely updates on clinical trial progress, strategic partnerships, and technology initiatives. Key content categories include cell therapy research milestones, AI/blockchain integration updates, financial disclosures, and acquisition announcements.
Our curated news collection enables stakeholders to monitor COEP’s progress in treating cancer and autoimmune diseases while tracking its expansion into automation and decentralized technologies. Bookmark this page for streamlined access to press releases and third-party analyses that matter to your investment strategy.
Coeptis Therapeutics Holdings (Nasdaq: COEP), a biopharmaceutical firm, announced that Dr. Colleen Delaney, Chief Scientific and Medical Officer, will present at the Allogeneic Cell Therapies Summit 6th Annual Meeting in Boston from June 10-12, 2024.
Dr. Delaney will deliver two key seminars on June 10: a panel discussion at 4:00 PM on the ideal starting materials for allogeneic products and a session at 5:30 PM on overcoming hurdles in allogeneic cell therapy using pooled donor cord blood CD34+ cells.
The Summit gathers leaders to discuss the future of allogeneic cell therapies, providing Coeptis with a platform to share its progress and innovations, especially with its universal SNAP-CAR technology aimed at reshaping cancer treatment.
Coeptis Therapeutics Holdings, a biopharmaceutical company, will present its innovative universal allogeneic SNAP-CAR NK cell therapy at the ISCT 2024 conference. This therapy has the potential to target multiple antigens, potentially avoiding toxicities and relapse. Coeptis expanded its license agreement for SNAP-CAR to include natural killer cells, aiming to develop a safer and cost-effective cellular therapy. The company's presentation at ISCT 2024 signifies a significant step towards universalizing the treatment of various diseases.
Coeptis Therapeutics Holdings, a biopharmaceutical company, will present data on the development of SNAP-CAR NK cells at the ASGCT Annual Meeting. The Company aims to revolutionize cancer treatment with a universal targeted cell therapy that eliminates the need for HLA matching.
FAQ
What is the current stock price of Coeptis Therapeutics (COEP)?
What is the market cap of Coeptis Therapeutics (COEP)?
